Shanxi Zhendong Pharmaceutical Co., Ltd.

Shanxi Zhendong Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing company listed on the ChiNext board of the Shenzhen Stock Exchange since 2011. The company specializes in the research, development, production, and sales of both generic and innovative drugs, focusing on various medical fields including oncology, dermatology, gastroenterology, urology, cardiology, and neurology. Additionally, Zhendong Pharmaceutical engages in the full industrial chain of traditional Chinese medicine, encompassing seedling cultivation, planting, processing, storage, and the production of decoction pieces. The company's notable products include the Compound Kushen Injection, a patented drug recognized for its efficacy in oncology, and Minoxidil Topical Solution, a leading treatment for androgenetic alopecia. The Compound Kushen Injection has been a significant part of clinical practice for three decades and is included in numerous national guidelines. Meanwhile, Dafeixin, the company's Minoxidil product, has achieved a substantial market share in hair regrowth solutions and is distinguished by its optimized formulation and safety profile. Zhendong Pharmaceutical is committed to integrating traditional Chinese medicine with Western medical practices to enhance treatment outcomes.

Compound Kushen Injection is an exclusive patented product of Zhendong Pharmaceutical and a key achievement under China's National Major New Drug Innovation Program. Launched in 1995, it has served clinical patients for three decades, earning widespread recognition for its proven efficacy, safety, and pharmacoeconomic advantages. With well-defined antitumor mechanisms, remarkable therapeutic effects, and high safety standards, it has garnered strong trust from clinicians and patients. To date, this injection has been included in over ten national authoritative guidelines and expert consensus recommendations, supported by substantial evidence-based medical evidence. Among comparable therapies, it has ranked first in clinical usage volume for three consecutive years. Minoxidil Topical Solution, the sole externally applied chemical drug recommended by the Chinese Guidelines for the Treatment of Androgenetic Alopecia, distinguishes Zhendong Dafeixin with its optimized formulation, reduced ethanol content, and enhanced safety profile, making it the preferred choice for non-cicatricial alopecia patients. Pioneering gender-specific treatment protocols, Dafeixin boasts nearly two decades of expertise in hair regeneration, with clinical validation confirming superior efficacy for male patients using the 5% concentration and female patients using the 2% formulation. Dominating the retail market for hair regrowth solutions, Dafeixin Minoxidil Topical Solution achieved a 47.3% market share in 2024, securing the West Lake Award for "Most Popular Pharmaceutical Product in Retail Pharmacies." It has established a novel "Integrated TCM-Western Medicine" ecosystem for comprehensive alopecia management.